Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-02-02 @ 12:46 AM
Study NCT ID:
NCT05266469
Status:
COMPLETED
Last Update Posted:
2025-07-09
First Post:
2022-02-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsing Multiple Sclerosis | View |